Therapeutic efficacy of
166Ho
U87 cells
animal model
glioblastoma
microbrachytherapy
minipig
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
04
2022
accepted:
30
09
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Glioblastoma is considered the most common malignant primary tumor of central nervous system. In spite of the current standard and multimodal treatment, the prognosis of glioblastoma is poor. For this reason, new therapeutic approaches need to be developed to improve the survival time of the glioblastoma patient. In this study, we performed a preclinical experiment to evaluate therapeutic efficacy of
Identifiants
pubmed: 36419904
doi: 10.3389/fonc.2022.923679
pmc: PMC9677531
doi:
Types de publication
Journal Article
Langues
eng
Pagination
923679Informations de copyright
Copyright © 2022 Khoshnevis, Brown, Belluco, Zahi, Maciocco, Bonnefont-Rebeix, Pillet-Michelland, Tranel, Roger, Nennig, Oudoire, Marcon, Tillement, Louis, Gehan, Bardiès, Mariani, Muzio, Meunier, Duchemin, Michel, N’Tsiba, Haddad, Buronfosse, Carozzo and Ponce.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:1092-102
pubmed: 27612807
Contemp Oncol (Pozn). 2014;18(5):307-12
pubmed: 25477751
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Neuro Oncol. 2008 Jun;10(3):361-7
pubmed: 18401015
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):15-25
pubmed: 27743773
Neurosurgery. 1987 Aug;21(2):201-6
pubmed: 2821446
Br J Neurosurg. 1999 Jun;13(3):256-64
pubmed: 10562835
J Neurosci Methods. 2017 Apr 15;282:61-68
pubmed: 28284687
Immunol Rev. 2017 Nov;280(1):231-248
pubmed: 29027224
Sci Transl Med. 2020 Feb 12;12(530):
pubmed: 32051227
J Neurosci Nurs. 2013 Oct;45(5):317
pubmed: 24025471
Int J Mol Sci. 2020 Jun 28;21(13):
pubmed: 32605154
PLoS One. 2013;8(1):e54526
pubmed: 23349919
Rep Pract Oncol Radiother. 2014 Aug 28;20(1):12-21
pubmed: 25535579
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Perm J. 2008 Fall;12(4):45-8
pubmed: 21339920
PLoS One. 2013;8(1):e52178
pubmed: 23320070
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
pubmed: 231022
Phys Med Biol. 2004 Oct 7;49(19):4543-61
pubmed: 15552416
Trends Cancer. 2015 Dec;1(4):252-265
pubmed: 27088132
Int J Mol Sci. 2014 Jan 10;15(1):927-43
pubmed: 24434638
Neuro Oncol. 1999 Jan;1(1):69-80
pubmed: 11550304
World Neurosurg. 2018 Jul;115:e59-e66
pubmed: 29631083
Methods Mol Biol. 2013;1004:3-15
pubmed: 23733565
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):97-111
pubmed: 28660349
J Neurooncol. 2017 Feb;131(3):593-601
pubmed: 27844308
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
J Radiat Res. 2010;51(4):393-404
pubmed: 20679741
Yonsei Med J. 2005 Feb 28;46(1):51-60
pubmed: 15744805
Biomed Res Int. 2017;2017:8013575
pubmed: 28316990
Cell Biochem Biophys. 2014 Dec;70(3):1625-31
pubmed: 25182001
Oncotarget. 2018 May 4;9(34):23532-23542
pubmed: 29805753
Cancer Radiother. 2014 Dec;18(8):770-8
pubmed: 25451674
Clin Adv Hematol Oncol. 2007 Nov;5(11):894-902, 907-15
pubmed: 18185489
Adv Drug Deliv Rev. 2017 May 15;114:206-221
pubmed: 28449873
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
PLoS One. 2020 Jun 18;15(6):e0234772
pubmed: 32555746